Founded by Toyoji Naito in December 1941, in just under 80 years, Eisai has become a leading global biopharma player, with pharmaceutical revenues of USD 5.4 billion in 2019. The company’s central philosophy of human health care (hhc) was…
The latest from Japanese pharma, including Takeda’s big profit jump, British Linepharma’s quest to get the first ever induced abortion pill for practical use, Shionogi’s promise to become the first…
Writing in the July issue of DIA’s Global Forum magazine Pfizer R&D Japan’s Atsushi Kitamura examines how both pharmaceutical companies and patients in Japan can help increase patient engagement in…
Writing in the October edition of DIA’s Global Forum magazine, Chief Executive of Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) Yasuhiro Fujiwara outlines how his agency has begun to utilise…
Dr Ken-ichiro Hata, representative director and chairperson of Japan’s Forum for Innovative Regenerative Medicine (FIRM) outlines the organisation’s mandate, how Japan has been able to cultivate one of the world’s…
Experienced global leader Takafumi Horii explains the rationale behind returning to his home nation of Japan to head up Takeda’s Japan Oncology operations. Horii also touches on the significant burden…
Ivan Cheung, head of Japanese firm Eisai’s US operations, highlights the significance of a potential 2021 US FDA approval for Alzheimer’s Disease drug aducanumab, developed in collaboration with Biogen. Cheung…
Writing in the June edition of DIA’s Global Forum magazine, representatives of Japanese pharmaceutical companies with US operations outline how the COVID-19 pandemic affected their ongoing clinical studies. The…
Writing in the May edition of DIA’s Global Forum magazine, Toshiyoshi Tominaga of the Asia-Pacific Self-Medication Industry (APSMI) looks at the landscape for OTC medicines in the Asia-Pacific region today. Tominaga highlights…
“This marks a significant moment in Takeda’s history and is an exciting step forward as we accelerate our transformation journey,” said Christophe Weber, Takeda’s CEO, after the USD 62 billion…
Toshio Fujimoto, MD, MBA, the General Manager of Shonan Health Innovation Park examines why Japan – despite being well established as one of the world’s most innovative and technologically advanced…
Writing in the August edition of DIA’s Global Forum, Kotone Matsuyama of the Nippon Medical School gives a run-through of Japan’s response to the COVID-19 pandemic, from the organisation and communication…
Japanese pharma companies are already far lower-profile than their occidental counterparts but an even lesser-known player may be Taiho Pharmaceutical, a Japanese specialty pharma player that was a pioneer in…
See our Cookie Privacy Policy Here